Xuefeng Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuefeng Hou has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Lihua Li
Drug Research and Development Center, School of Pharmacy, Wannan Medical University, Wuhu 241002, China
3 shared publications - Chi Zhang
Drug Research and Development Center, School of Pharmacy, Wannan Medical University, Wuhu 241002, China
2 shared publications - Chunfei Wang
Drug Research and Development Center, School of Pharmacy, Wannan Medical University, Wuhu 241002, China
2 shared publications - Haonan Qiu
Drug Research and Development Center, School of Pharmacy, Wannan Medical University, Wuhu 241002, China
2 shared publications - Lutan Zhou
Drug Research and Development Center, School of Pharmacy, Wannan Medical University, Wuhu 241002, China
2 shared publications - Yu Zhang
Drug Research and Development Center, School of Pharmacy, Wannan Medical University, Wuhu 241002, China
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 1036
N-Acetylcysteine-Functionalized Mixed Micelles Overcome Multiple Intestinal Barriers to Improve Oral Bioavailability and Antioxidant Protection of Imperatorin
Background: Imperatorin (IPT) is a natural furanocoumarin featuring robust anti-inflammatory, antifibrotic and antioxidant activities. However, poor aqueous solubility and insufficient oral bioavailability restrict its clinical application. Multiple gastrointestinal barriers, including the mucus barrier, limited epithelial penetration and P-glycoprotein-triggered drug efflux, are major obstacles hindering IPT oral absorption. Methods: N-acetylcysteine (NAC)-functionalized TPGS conjugates were synthesized first. Using Pluronic® F108 and Lipoid® S-100 as a matrix, imperatorin@N-acetylcysteine-TPGS/Pluronic® F108/Lipoid® S-100 (IPT@NAC-TFS) micelles were fabricated. We characterized their physicochemical features and in vitro release behavior. The Caco-2/HT29-MTX-E12 co-culture cell model was adopted to explore mucus permeation, cellular uptake and transepithelial transport mechanisms. In vivo intestinal distribution and pharmacokinetic tests in rats were carried out to confirm the oral absorption-enhancing effect of micelles. Results: Optimized micelles displayed a uniform shape and favorable encapsulation efficiency. Low CMC maintained structural stability upon gastrointestinal dilution. NAC modification conferred mucus-penetrating capacity on micelles. TPGS simultaneously improved epithelial barrier permeability and inhibited drug efflux, switching IPT transport mode. The micelles effectively cleared intracellular ROS, recovered SOD activity and lowered MDA levels in BLM-impaired MLg fibroblasts. In vivo results revealed enhanced intestinal drug accumulation, with the relative oral bioavailability of IPT increased by 6.07-fold. Conclusions: IPT@NAC-TFS micelles overcome multiple gastrointestinal barriers for oral IPT delivery. Combining mucus penetration, efflux suppression and antioxidative capacity, this system offers a promising strategy to develop oral formulations of poorly soluble antifibrotic natural products.
- 20 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 1036
Open AccessN-Acetylcysteine-Functionalized Mixed Micelles Overcome Multiple Intestinal Barriers to Improve Oral Bioavailability and Antioxidant Protection of Imperatorin
Background: Imperatorin (IPT) is a natural furanocoumarin featuring robust anti-inflammatory, antifibrotic and antioxidant activities. However, poor aqueous solubility and insufficient oral bioavailability restrict its clinical application. Multiple gastrointestinal barriers, including the mucus barrier, limited epithelial penetration and P-glycoprotein-triggered drug efflux, are major obstacles hindering IPT oral absorption. Methods: N-acetylcysteine (NAC)-functionalized TPGS conjugates were synthesized first. Using Pluronic® F108 and Lipoid® S-100 as a matrix, imperatorin@N-acetylcysteine-TPGS/Pluronic® F108/Lipoid® S-100 (IPT@NAC-TFS) micelles were fabricated. We characterized their physicochemical features and in vitro release behavior. The Caco-2/HT29-MTX-E12 co-culture cell model was adopted to explore mucus permeation, cellular uptake and transepithelial transport mechanisms. In vivo intestinal distribution and pharmacokinetic tests in rats were carried out to confirm the oral absorption-enhancing effect of micelles. Results: Optimized micelles displayed a uniform shape and favorable encapsulation efficiency. Low CMC maintained structural stability upon gastrointestinal dilution. NAC modification conferred mucus-penetrating capacity on micelles. TPGS simultaneously improved epithelial barrier permeability and inhibited drug efflux, switching IPT transport mode. The micelles effectively cleared intracellular ROS, recovered SOD activity and lowered MDA levels in BLM-impaired MLg fibroblasts. In vivo results revealed enhanced intestinal drug accumulation, with the relative oral bioavailability of IPT increased by 6.07-fold. Conclusions: IPT@NAC-TFS micelles overcome multiple gastrointestinal barriers for oral IPT delivery. Combining mucus penetration, efflux suppression and antioxidative capacity, this system offers a promising strategy to develop oral formulations of poorly soluble antifibrotic natural products.
- Open Access
Development of Imperatorin Nanostructured Lipid Carriers with Grape Seed Oil for Boosting Oral Absorption and Antioxidant Capacity
Imperatorin (IPT) is a naturally occurring coumarin with recognized antioxidant and anti-aging properties; unfortunately, its poor water solubility and low oral bioavailability severely limit its practical use. To get around these issues, we formulated IPT-loaded NLCs using grape seed oil and glyceryl monostearate—both food-grade excipients—with the goal of enhancing oral absorption. Optimized IPT@NLCs were prepared by high-pressure homogenization, featuring uniform spherical morphology, an average particle size of 186.63 ± 1.65 nm, a PDI of 0.188 ± 0.008, an encapsulation efficiency of 99.54 ± 0.10%, and a drug loading capacity of 9.08 ± 0.23%. IPT@NLCs remained stable in SGF, while their cumulative in vitro release over 48 h reached 90.56 ± 3.12% in SIF. We established a Caco-2/HT29-MTX-E12 co-culture monolayer to examine mucus penetration, cellular uptake, and transcellular transport routes. In parallel, oxidative stress experiments using 3T3-L1 cells, along with in vivo pharmacokinetic and gastrointestinal safety evaluations, were conducted to provide complementary evidence. Our results indicate that NLC encapsulation significantly improves both the dissolution and intestinal uptake of IPT, primarily by shifting the absorption mechanism from passive diffusion to energy-dependent active transport. In addition, IPT@NLCs effectively reduce intracellular oxidative damage through modulation of endogenous antioxidant enzyme activities. Animal studies further reveal an approximately 9-fold increase in relative oral bioavailability, with no notable irritation to gastrointestinal tissues. Overall, GSO-based NLCs offer safe and efficient oral delivery, enhancing IPT bioavailability and antioxidant activity, providing a strategy for developing natural-product-based formulations.
Open AccessDevelopment of Imperatorin Nanostructured Lipid Carriers with Grape Seed Oil for Boosting Oral Absorption and Antioxidant Capacity
Imperatorin (IPT) is a naturally occurring coumarin with recognized antioxidant and anti-aging properties; unfortunately, its poor water solubility and low oral bioavailability severely limit its practical use. To get around these issues, we formulated IPT-loaded NLCs using grape seed oil and glyceryl monostearate—both food-grade excipients—with the goal of enhancing oral absorption. Optimized IPT@NLCs were prepared by high-pressure homogenization, featuring uniform spherical morphology, an average particle size of 186.63 ± 1.65 nm, a PDI of 0.188 ± 0.008, an encapsulation efficiency of 99.54 ± 0.10%, and a drug loading capacity of 9.08 ± 0.23%. IPT@NLCs remained stable in SGF, while their cumulative in vitro release over 48 h reached 90.56 ± 3.12% in SIF. We established a Caco-2/HT29-MTX-E12 co-culture monolayer to examine mucus penetration, cellular uptake, and transcellular transport routes. In parallel, oxidative stress experiments using 3T3-L1 cells, along with in vivo pharmacokinetic and gastrointestinal safety evaluations, were conducted to provide complementary evidence. Our results indicate that NLC encapsulation significantly improves both the dissolution and intestinal uptake of IPT, primarily by shifting the absorption mechanism from passive diffusion to energy-dependent active transport. In addition, IPT@NLCs effectively reduce intracellular oxidative damage through modulation of endogenous antioxidant enzyme activities. Animal studies further reveal an approximately 9-fold increase in relative oral bioavailability, with no notable irritation to gastrointestinal tissues. Overall, GSO-based NLCs offer safe and efficient oral delivery, enhancing IPT bioavailability and antioxidant activity, providing a strategy for developing natural-product-based formulations.
- Open Access
Electrochemical Sensing of Doxorubicin in Breast Cancer Cells Based on Membrane-Permeation Strategy
Monitoring the concentration of doxorubicin (DOX) was critical for tumor treatment, but existing methods failed to cross cell membrane. Here, an electrochemical platform for intracellular DOX detection in MCF-7 cells based on membrane-permeation strategy was developed. A modified gold electrode was prepared via electrodepositing AuNPs and assembling SH-DNA. Concurrently, the silica nanosphere/gold nanocluster-circular transmembrane peptide (SiO2/AuNCs-iRGD) composite nanoparticles with membrane permeability, tumor targeting, and imaging capability were synthesized. After co-incubation of SiO2/AuNCs-iRGD with MCF-7 cells and DOX, followed by co-incubation with the DNA-modified electrode, intracellular DOX intercalated into the DNA backbone, and redox-generated electrons were transferred to the electrode to produce a concentration-correlated electrochemical signal. The modification of the electrode, the morphology of the composite nanoparticles and the detection process were characterized by means of SEM, TEM, CV, EIS, DPV, fluorescence spectroscopy and laser confocal imaging. Under the optimized conditions, the proposed method exhibited a wide detection range of 0.05–300 μmol/L, with a detection limit of 0.01 μmol/L. Moreover, the modified electrode demonstrated satisfactory regenerability, and the proposed method showed excellent reproducibility and stability. The development platform could offer a new strategy for real-time assessment of drug concentration within cultured breast cancer cells in vitro.
Open AccessElectrochemical Sensing of Doxorubicin in Breast Cancer Cells Based on Membrane-Permeation Strategy
Monitoring the concentration of doxorubicin (DOX) was critical for tumor treatment, but existing methods failed to cross cell membrane. Here, an electrochemical platform for intracellular DOX detection in MCF-7 cells based on membrane-permeation strategy was developed. A modified gold electrode was prepared via electrodepositing AuNPs and assembling SH-DNA. Concurrently, the silica nanosphere/gold nanocluster-circular transmembrane peptide (SiO2/AuNCs-iRGD) composite nanoparticles with membrane permeability, tumor targeting, and imaging capability were synthesized. After co-incubation of SiO2/AuNCs-iRGD with MCF-7 cells and DOX, followed by co-incubation with the DNA-modified electrode, intracellular DOX intercalated into the DNA backbone, and redox-generated electrons were transferred to the electrode to produce a concentration-correlated electrochemical signal. The modification of the electrode, the morphology of the composite nanoparticles and the detection process were characterized by means of SEM, TEM, CV, EIS, DPV, fluorescence spectroscopy and laser confocal imaging. Under the optimized conditions, the proposed method exhibited a wide detection range of 0.05–300 μmol/L, with a detection limit of 0.01 μmol/L. Moreover, the modified electrode demonstrated satisfactory regenerability, and the proposed method showed excellent reproducibility and stability. The development platform could offer a new strategy for real-time assessment of drug concentration within cultured breast cancer cells in vitro.
- Open Access
- 6 July 2023
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 61 (1) , 1000-1012
Hyperoside ameliorates cerebral ischaemic–reperfusion injury by opening the TRPV4 channel in vivo through the IP 3 -PKC signalling pathway
Hyperoside (Hyp), one of the active flavones from Rhododendron (Ericaceae), has beneficial effects against cerebrovascular disease. However, the effect of Hyp on vasodilatation has not been elucidated. To explore the effect of Hyp on vasodilatation in the cerebral basilar artery (CBA) of Sprague-Dawley (SD) rats suffering with ischaemic–reperfusion (IR) injury. Sprague-Dawley rats were randomly divided into sham, model, Hyp, Hyp + channel blocker and channel blocker groups. Hyp (50 mg/kg, IC50 = 18.3 μg/mL) and channel blocker were administered via tail vein injection 30 min before ischaemic, followed by 20 min of ischaemic and 2 h of reperfusion. The vasodilation, hyperpolarization, ELISA assay, haematoxylin–eosin (HE), Nissl staining and channel-associated proteins and qPCR were analysed. Rat CBA smooth muscle cells were isolated to detect the Ca2+ concentration and endothelial cells were isolated to detect apoptosis rate. Hyp treatment significantly ameliorated the brain damage induced by IR and evoked endothelium-dependent vasodilation rate (47.93 ± 3.09% vs. 2.99 ± 1.53%) and hyperpolarization (–8.15 ± 1.87 mV vs. −0.55 ± 0.42 mV) by increasing the expression of IP3R, PKC, transient receptor potential vanilloid channel 4 (TRPV4), IKCa and SKCa in the CBA. Moreover, Hyp administration significantly reduced the concentration of Ca2+ (49.08 ± 7.74% vs. 83.52 ± 6.93%) and apoptosis rate (11.27 ± 1.89% vs. 23.44 ± 2.19%) in CBA. Furthermore, these beneficial effects of Hyp were blocked by channel blocker. Although Hyp showed protective effect in ischaemic stroke, more clinical trial certification is needed due to the difference between animals and humans.
- 6 July 2023
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 61 (1) , 1000-1012
Open AccessHyperoside ameliorates cerebral ischaemic–reperfusion injury by opening the TRPV4 channel in vivo through the IP 3 -PKC signalling pathway
Hyperoside (Hyp), one of the active flavones from Rhododendron (Ericaceae), has beneficial effects against cerebrovascular disease. However, the effect of Hyp on vasodilatation has not been elucidated. To explore the effect of Hyp on vasodilatation in the cerebral basilar artery (CBA) of Sprague-Dawley (SD) rats suffering with ischaemic–reperfusion (IR) injury. Sprague-Dawley rats were randomly divided into sham, model, Hyp, Hyp + channel blocker and channel blocker groups. Hyp (50 mg/kg, IC50 = 18.3 μg/mL) and channel blocker were administered via tail vein injection 30 min before ischaemic, followed by 20 min of ischaemic and 2 h of reperfusion. The vasodilation, hyperpolarization, ELISA assay, haematoxylin–eosin (HE), Nissl staining and channel-associated proteins and qPCR were analysed. Rat CBA smooth muscle cells were isolated to detect the Ca2+ concentration and endothelial cells were isolated to detect apoptosis rate. Hyp treatment significantly ameliorated the brain damage induced by IR and evoked endothelium-dependent vasodilation rate (47.93 ± 3.09% vs. 2.99 ± 1.53%) and hyperpolarization (–8.15 ± 1.87 mV vs. −0.55 ± 0.42 mV) by increasing the expression of IP3R, PKC, transient receptor potential vanilloid channel 4 (TRPV4), IKCa and SKCa in the CBA. Moreover, Hyp administration significantly reduced the concentration of Ca2+ (49.08 ± 7.74% vs. 83.52 ± 6.93%) and apoptosis rate (11.27 ± 1.89% vs. 23.44 ± 2.19%) in CBA. Furthermore, these beneficial effects of Hyp were blocked by channel blocker. Although Hyp showed protective effect in ischaemic stroke, more clinical trial certification is needed due to the difference between animals and humans.
- 3 November 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (1) , 84-94
Longitudinal associations of serum survivin with the severity and prognosis of community-acquired pneumonia patients
- 3 November 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (1) , 84-94
Longitudinal associations of serum survivin with the severity and prognosis of community-acquired pneumonia patients